HC2 Holdings Portfolio Company R2 Technologies Disrupts the Aesthetics Industry with Launch of Its Groundbreaking Glacial Rx Treatment - Seite 2

• Cool: The cold plate is applied to a spot for 15-20 seconds; no topical anesthetics or numbing agents needed.
• Calm: The cooling handpiece is gently moved across the face to reduce redness and puffiness, clearing the way for skin to better absorb potent topicals.
• Protect: Serums containing protective antioxidants and brightening agents can be applied, shielding the skin from environmental aggressors. Post-treatment take-home topical offerings, formulated with skin-beneficial plant derived actives, aid in skin recovery, accelerate skin’s desquamation process and re-epithelialization, and dramatically boost antioxidant activity to fight free radical damage.
  

“It took us a long time to ensure that we were creating a best-in-class treatment, giving unparalleled results and superior experiences to our patients, and we are thrilled to finally bring this matchless innovation to market,” says Tim Holt, R2 Chief Executive Officer. According to a recent clinical study, 93% of spots improved at 2 months¹; and another showed that 90% of patients said their skin was rejuvenated, brighter or more even at 1 month.²

Launching this month in dermatology offices and med spas nationwide, Glacial Rx was named among ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading and most trusted source to educate on cosmetic procedures. R2 is continuing to facilitate Glacial Rx system orders for practices to offer the treatment. Learn more about R2 Technologies and Glacial Rx at glacialskin.com and follow the company on LinkedIn.

About HC2
HC2 Holdings, Inc. (NYSE: HCHC) has a class-leading portfolio of innovative assets primarily in Infrastructure, Life Sciences and Spectrum. HC2 is headquartered in New York, New York, and through its subsidiaries employs 2,864 people.

About Pansend Life Sciences
Pansend Life Sciences, LLC is the life sciences subsidiary of HC2 Holdings, Inc., focused on the development of innovative healthcare technologies and products. Pansend’s portfolio companies include R2 Technologies, which is developing medical devices for the treatment of aesthetic and medical skin conditions and has received FDA approval for its initial device; MediBeacon, whose proprietary platform technology is the foundation of its development of a non-invasive real-time monitoring system for the evaluation of kidney function; Triple Ring, a leading edge research, engineering and development firm which specializes in regulated medical devices, in vitro diagnostics & life sciences tools as well as imaging, and industrial applications; and Genovel Orthopedics, which is developing novel partial and total knee replacements for the treatment of osteoarthritis of the knee.